N-(2-hydroxy-1-hydroxymethyl-ethyl)-3-phenyl-propionamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-hydroxy-1-hydroxymethyl-ethyl)-3-phenyl-propionamide
• 英文别名: N-(1,3-dihydroxypropan-2-yl)-3-phenylpropanamide
• 化学式: C₁₂H₁₇NO₃
• 分子量: 223.272
• InChiKey: AZWQVSYSKPSDLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(2-hydroxy-1-hydroxymethyl-ethyl)-3-phenyl-propionamide 、 对羟基苯甲醛 、 对甲苯磺酸 在 二氯甲烷 、 乙酸乙酯 、 trans-N-12-(4-hydroxy-phenyl)-[1,3]dioxan-5-yl 、 H+ 作用下， 以 甲苯 为溶剂， 反应 3.0h， 以yielding trans-N-12-(4-hydroxy-phenyl)-[1,3]dioxan-5-yl]-3-phenyl-propionamide (1.41 g, MS: m/e=328.2 (M+H+))的产率得到3-苯基丙酰胺
  参考文献：
  名称：

  US06184236B2

  摘要：

  公开号：
• 作为产物：
  描述：

  丝氨醇 、 3-苯基丙酸 以 二氯甲烷 为溶剂， 以56%的产率得到N-(2-hydroxy-1-hydroxymethyl-ethyl)-3-phenyl-propionamide
  参考文献：
  名称：

  US6184236

  摘要：

  公开号：

文献信息

• Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0982026A2

  公开（公告）日：2000-03-01

  The present invention relates to the use of compounds of the general formula wherein Ar1is phenyl, naphthyl or tetrahydronaphthyl, optionally substituted by hydroxy, lower alkoxy, nitro, amino or methanesulfonamide; Ar2is phenyl, naphthyl or tetrahydronaphthyl, optionally substituted by lower alkyl or halogen; Xis C, CH, C(OH) or N; Yis -CH2-, CH or O Z-CH2-, -CH(CH3)- or -C(CH3)2-; R1is hydrogen, lower alkyl or acetyl; Ais C=O or -(CHR2)n-, wherein R2 is hydrogen, lower alkyl or hydroxy-lower alkyl; Bis -(CH2)n-, O, -CH(OH)(CH2)n-, -CH(CH2OH)(CH2)n-, -(CH2)n CH(OH)- or -CH(CH2OH)-; ---may be a bond and nis 0-4 and to pharmaceutically acceptable acid addition salts thereof for the manufacture of medicaments which represent therapeutic indications for NMDA receptor subtype specific blockers.

  本发明涉及通式化合物的用途 式中 Ar1 是苯基、萘基或四氢萘基，可选择被羟基、低级烷氧基、硝基、氨基或甲磺酰胺取代； Ar2 是苯基、萘基或四氢萘基，可选择被低级烷基或卤素取代； X 是 C、CH、C(OH) 或 N； Y 是-CH2-、CH 或 O Z-CH2-、-CH(CH3)- 或 -C(CH3)2-； R1 是氢、低级烷基或乙酰基； A 是 C=O 或 -(CHR2)n-，其中 R2 是氢、低级烷基或羟基低级烷基； 双-(CH2)n-、O、-CH(OH)(CH2)n-、-CH(CH2OH)(CH2)n-、-(CH2)n CH(OH)-或-CH(CH2OH)-； ---可为键且 n 为 0-4 及其药学上可接受的酸加成盐，用于制造代表 NMDA 受体亚型特异性阻断剂治疗适应症的药物。
• N-Acylation Reactions Performed in Aqueous Reaction Medium:  Screening and Optimising of a Synthetic Step of a Process for Iodixanol
  作者：Hans-René Bjørsvik、Torgrim Engell

  DOI：10.1021/op010078f

  日期：2002.3.1

  This contribution presents results from a development and optimisation project concerning a synthetic process for iodixanol. Iodixanol is the "active ingredient" in Visipaque (Nycomed Amersham now Amersham Health) a medical X-ray imaging contrast agent. The process step that was developed and optimised comprised a reaction between a tetraacid chloride and 3-aminopropane-1,2-diol for obtaining the corresponding tetraamide. This reaction was originally performed using DMA as reaction medium, a reaction that gave a medium-to-high yield of the tetraamide. Solvent screening was performed followed by process optimisation using response surface methodology. Surprisingly, a solvent mixture composed by 1:2 v/v THF:water was determined to be a superb reaction medium. Tuning the experimental condition according to the developed multivariate empirical model gave an excellent yield of the target molecule, nearly 94% with only small quantities of the main side product, monoacid triamide, which indicates a rather low hydrolytic degradation of the substrate. The current synthetic process step to iodixanol showed also a general validity when a small variety of amino alcohols and acid chlorides were reacted to successfully obtain the desired amides in high yields, concomitant with low outcomes of the most likely side products, that is the hydrolysis products of the acid chlorides.
• US6184236B1
  申请人：——

  公开号：US6184236B1

  公开（公告）日：2001-02-06
• US6184236
  申请人：——

  公开号：——

  公开（公告）日：——
• US06184236B2
  申请人：——

  公开号：——

  公开（公告）日：——